Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2023 value amounting to $38.0 million.

  • Gyre Therapeutics' Shares Outstanding (Weighted Average) rose 2062.03% to $38.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $38.0 million, marking a year-over-year increase of 2062.03%. This contributed to the annual value of $31.5 million for FY2022, which is 295.27% up from last year.
  • Gyre Therapeutics' Shares Outstanding (Weighted Average) amounted to $38.0 million in Q3 2023, which was up 2062.03% from $37.8 million recorded in Q2 2023.
  • In the past 5 years, Gyre Therapeutics' Shares Outstanding (Weighted Average) registered a high of $38.0 million during Q3 2023, and its lowest value of $12.0 million during Q1 2019.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $26.2 million, with a median of $31.0 million in 2021.
  • Per our database at Business Quant, Gyre Therapeutics' Shares Outstanding (Weighted Average) soared by 9452.13% in 2021 and then surged by 33.39% in 2022.
  • Gyre Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $12.0 million in 2019, then surged by 59.53% to $19.2 million in 2020, then skyrocketed by 59.76% to $30.6 million in 2021, then grew by 2.95% to $31.5 million in 2022, then increased by 20.39% to $38.0 million in 2023.
  • Its last three reported values are $38.0 million in Q3 2023, $37.8 million for Q2 2023, and $37.8 million during Q1 2023.